ARTICLE | Clinical News
Gabapentin GR: Phase III start
September 22, 2008 7:00 AM UTC
Next quarter, Depomed will begin the double-blind, placebo-controlled Phase III Breeze 2 trial to evaluate 1,200 mg Gabapentin GR given once daily, or 600 mg Gabapentin GR in the morning plus 1,200 mg...